AKAkil Kaderbay

Akil Kaderbay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akil Kaderbay has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Frédéric Venail

    INM, INSERM, University of Montpellier, France

    2 shared publications
  • A.-L. Fourez

    From the Department of ENT and Head and Neck Surgery (A.-L.F., M.A., A.K., M.M., F.V.) and Neuroradiology (G.G., P.-H.L.), University Hospital Gui de Chauliac, and Department of Medical Information and Biostatistics (C.D.), University Hospital La Colombière, University of Montpellier, Montpellier, France

    1 shared publication
  • Alexandre Karkas

    Oto-Rhino-Laryngology, Head and Neck Surgery Department, Saint-Etienne University, Hôpital Nord, Saint Etienne, France

    1 shared publication
  • Ali Bouamrani

    Medimprint, 38700 La Tronche, France

    1 shared publication
  • Ashley Baguant

    Department of oto-rhino-laryngology, Grenoble Alpes University Hospital, Avenue Maquis du Grésivaudan, 38700 La Tronche, France; Braintech Lab, INSERM unit 1205, Grenoble Alpes University, 38400 Saint Martin D'heres, France; Grenoble Alpes University, 38000 Grenoble, France

    1 shared publication
  • Benoit Lepage

    Affiliation Methodological Research Support Unit, Faculty of Medicine, University of Toulouse, Toulouse, France

    1 shared publication

Latest Publications

  • Open Access

    INTerest of electrophysiological and functional EXploration in the evaluation of symptomatic impact of superior semicircular canal DEHIscence syndrome (INTEX-DEHI study): Study protocol for a reliability and validity study

    by Quentin Legois, Fabrice Giraudet, Yohan Gallois, Benoit Lepage, Eugen Ionescu, Jean-François Vellin, Valérie Franco-Vidal, Akil Kaderbay, Marie-Jeanne Vellin, French Association of Superior Semicircular Canal Dehiscence syndrome ,, et al.

    Background: Interest in Superior Semicircular Canal Dehiscence (SSCD) has increased, but its diagnosis and management remain challenging. Despite advances in imaging and electrophysiological tests, many patients face long diagnostic delays and significant distress due to unclear symptom severity. While some patients show no symptoms despite radiological evidence, others experience disabling effects. This research aims to bridge the gap between objective tests and symptom severity, improving the understanding and management of SSCD. Methods: This is a prospective, non-randomized, longitudinal observational clinical study including repeated measures. It is part of the inter-regional hospital research program “INTEX-DEHI”, involving five university hospitals. Patients diagnosed with unilateral superior semicircular canal dehiscence via CT scan will be followed over four weeks with three visits spaced 15 days apart. The main objective is to describe the clinical and paraclinical characteristics of SSCD and analyze their correlation. Electrophysiological, functional, and clinical measurements will be collected at each visit. Discussion: The relationship between electrophysiological tests and the symptomatic impact of superior semicircular canal dehiscence remains underexplored. This research aims to bridge this gap by studying both common and specific VEMP frequencies, as well as EcoG and WBT, to assess their sensitivity, specificity, and diagnostic value. While this study proposes innovative tools to objectively assess symptoms, challenges remain, particularly the underdiagnosis of the syndrome and selection biases, especially in patients with fluctuating symptoms. Additionally, the diversity of clinical presentations and the absence of symptoms in some patients complicate the interpretation of results. Trial registration: Clinicaltrials.gov, NCT06170398.

  • Miniaturized Endoscopic 2D US Transducer for Volumetric Ultrasound Imaging of the Auditory System

    by Lucas Lavenir, João C. Santos, Nabil Zemiti, Akil Kaderbay, Frédéric Venail, Philippe Poignet

    Objective: In this paper, we focus on the carrying out and validation of minimally invasive three-dimensional (3D) ultrasound (US) imaging of the auditory system, which is based on a new miniaturized endoscopic 2D US transducer. Methods: This unique probe consists of a 18 MHz 24 elements curved array transducer with a distal diameter of 4 mm so it can be inserted into the external auditory canal. Typical acquisition is achieved by rotating such a transducer around its own axis using a robotic platform. Reconstruction of a US volume from the set of acquired B-scans during the rotation is then performed using scan-conversion. The accuracy of the reconstruction procedure is evaluated using a dedicated phantom that includes a set of wires as reference geometry. Results: Twelve acquisitions obtained from different probe poses are compared to a micro-computed tomographic model of the phantom, leading to a maximum error of 0.20 mm. Additionally, acquisitions with a cadaveric head highlight the clinical applicability of this set up. Structures of the auditory system such as the ossicles and the round window can be identified from the obtained 3D volumes. Conclusion: These results confirm that our technique enables the accurate imaging of the middle and inner ears without having to deteriorate the surrounding bone. Significance: Since US is a real-time, wide available and non-ionizing imaging modality, our acquisition setup could facilitate the minimally invasive diagnosis and surgical navigation for otology in a fast, cost-effective and safe way.


  • Balloon dilation for persistent unilateral chronic obstructive Eustachian tube dysfunction is effective: a prospective multicentre study

    by Akil Kaderbay, Alexandre Karkas, David Schmitt, Thibault Mura, Jean Pierre Lavieille, Frédéric Venail

    Purpose Balloon dilatation of the Eustachian tube (BDET) is an option for treating chronic obstructive Eustachian tube dysfunction (COETD). In this prospective multicentric study, the main objective was to evaluate the results of BDET in unilateral COETD refractory to medical treatment. Methods Adults with unilateral COETD whose Eustachian Tube Score (ETS) was less than 5 despite medical pressure therapy were included. The primary endpoint was the change in ETS measured at 2, 6, and 12 months after BDET. Secondary objectives were the evolution of clinical symptoms assessed by the Eustachian Tube Questionnaire (ETDQ-7), audiometry, tympanometry, and otoscopy changes after BDET. Results Twenty-eight patients were included between May 2014 and December 2017 and were treated with BDET without adverse effects in three different referral centers. Population’s median age was 52 (Q25; Q75: 24, 82) years. The median follow-up time was 381 (Q25; Q75: 364; 418) days. The median ETS was 2 (Q25; Q75: 1; 4) before BDET. There was a significant improvement in ETS at 2 and 6 months and 1 year after BDET (score at 1 year: 6 (Q25; Q75: 2; 8) (p < 0.0001)). There was a significant, sustained improvement in the ETDQ-7 with a score of 4.21 (Q25; Q75–3.50; 4.79) before BDET and 3.43 (Q25; Q75–2.43; 4.14) (p = 0.0012) at 1 year. There was a suggestive improvement in tympanometry results at 1 year (p = 0.025). Conclusion BDET provides an improvement in symptoms and objective measures assessed at 1 year in patients with COETD who have failed medical treatment. Trial Registration: NCT02123277 (April 25, 2014).


  • Perilymph metabolomic and proteomic MALDI-ToF profiling with porous silicon chips: A proof-of-concept study

    by Akil Kaderbay, François Berger, Ali Bouamrani, Marie Bidart, Graciane Petre, Ashley Baguant, Ludovic Giraud, Sébastien Schmerber


  • Optimal Duration of MRI Follow-up to Safely Identify Middle Ear Residual Cholesteatoma

    by A.-L. Fourez, M. Akkari, G. Gascou, P.-H. Lefevre, C. Duflos, A. Kaderbay, M. Mondain, F. Venail

    BACKGROUND AND PURPOSE: Previous studies have demonstrated the usefulness of non-EPI DWI for detection of residual cholesteatoma. However, limited data are available to determine the suitable duration of imaging follow-up after a first MR imaging with normal findings has been obtained. The present study aimed to determine the optimal duration of non-EPI DWI follow-up for residual cholesteatoma. MATERIALS AND METHODS: A retrospective, monocentric study was performed between 2013 and 2019 and included all participants followed up after canal wall up tympanoplasty with at least 2 non-EPI DWI examinations performed on the same 1.5T MR imaging scanner. MR images were reviewed independently by 2 radiologists. Sensitivity and specificity values were calculated as a function of time after the operation. Receiver operating characteristic curves were analyzed to determine the optimal follow-up duration. RESULTS: We analyzed 47 MRIs from 17 participants. At the end of the individual follow-up period, a residual cholesteatoma had been found in 41.1% of cases. The follow-up duration ranged from 20 to 198 months (mean, 65.9 [SD, 43.9] months). Participants underwent between 2 and 5 non-EPI DWI examinations. Analyses of the receiver operating characteristic curves revealed that the optimal diagnostic value of non-EPI DWI occurred 56 months after the operation when the first MR imaging performed a mean of 17.3 (SD, 6.8) months after the operation had normal findings (sensitivity = 0.71; specificity = 0.7, Youden index = 0.43). CONCLUSIONS: Repeat non-EPI DWI is required to detect slow-growing middle ear residual cholesteatomas. We, therefore, recommend performing non-EPI DWI for at least the first 5 years after the initial operation.


  • Malnutrition and refeeding syndrome prevention in head and neck cancer patients: from theory to clinical application

    by Akil Kaderbay, Ihab Atallah, Eric Fontaine, Marine Chobert-Bakouline, Stephanie Schmitt, Philipp Mitariu, Christian Adrien Righini

    The goal of this review is to raise awareness about refeeding syndrome (RFS) and to give a comprehensive presentation of recent guidelines and latest scientific data about nutritional management among head and neck cancer (HNC) patients while focusing on RFS prevention.